Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario

Published: October 23, 2016
Category: Bibliography
Authors: Jacob McGee, Karen Panabaker, Laurie Elit, Peter Ainsworth, Salimah Z. Shariffb, Sean Leonard
Countries: Canada
Language: English
Types: Care Management, Population Health
Settings: Hospital

Objective: In 2001, the province of Ontario expanded cancer genetic testing eligibility to include all women with high-grade serous ovarian carcinoma (HGSC) of the ovary, fallopian tube, and peritoneum. The aim of this study was to determine the proportion of women who attended genetics counseling for consideration of BRCA1/2 gene analysis. We also sought to examine if regional differences in consultation rate exist across administrative health regions in the province of Ontario.

Methods: We identified all women with a pathological diagnosis of HGSC in the province of Ontario between 1997 until 2011. Our primary outcome was the 2-year rate of genetics consultation following a diagnosis of HGSC. We compared consultation rates over time and geographical regions and applied multiple logistic regression to identify predictors of genetics consultation.

Results: Of the 5412 women with a diagnosis of HGSC over the study period, 6.6% were seen for genetics consultation within 2 years of diagnosis. Factors predictive of genetics consultation included history of breast cancer (odds ratio [OR], 3.56; 95% confidence interval [CI], 1.87Y6.78), era of diagnosis (2009Y2011 vs 1997Y2000; OR, 10.59; 95% CI, 5.02Y22.33), and younger age at diagnosis (OR, 0.95; 95% CI, 0.94Y0.97 for each additional year). No regional differences in consultation rate were seen.

Conclusions: Despite an increasing rate across eras, a small proportion of women with HGSC undergo genetics consultation. Efforts are required to increase cancer genetics consultation in patients with HGSC in the province of Ontario.

High-Impact Chronic Conditions,Practice Patterns Comparison,Population Markers,Gender,Canada,BRCA Mutation,Genetics Consultation,Ovarian Carcinoma,Risk Reducing
LinkedIn Facebook Twitter

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System.
All rights reserved. Terms of Use Privacy Statement

Back to top